The sodium-glucose cotransporter 2 (SGLT2) inhibitors are essential for treating diabetes in lipodystrophic patients due to their insulin-independent effect and notable cardio-renal benefits. This evidence concerns the gene SLC5A2 and diabetes mellitus.